Suggest Saving Ezetimibe as an Add-On in High-Risk Patients

January 2015

Controversy over the role of ezetimibe (Zetia, etc) and the pros and cons of aiming for LDL goals will heat up...again.

Ezetimibe fell out of favor several years ago...when a study showed that adding ezetimibe to simvastatin did NOT work better than simvastatin alone to slow atherosclerosis progression.

Now the big new "IMPROVE-IT" trial shows that adding ezetimibe to simvastatin 40 mg reduces CV events compared to simvastatin alone.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote